Presented herein are methods of treating cancer, for example, RAFi-resistant melanoma, using a combination of a bromodomain inhibitor such as JQ1, together with either a MEK inhibitor (e.g., MEKi) or a BRAF inhibitor (e.g., RAFi). These combinations were identified from candidate combinations produced by a cell type-specific, quantitative network model of signaling in cells (e.g., melanoma) to predict cellular response to untested combinatorial perturbations.
